Matthew J Schurman

7356365, Apr 8, 2008

Jul 2, 2004

10/884298

Matthew J. Schurman - Somerset NJ, US

GlucoLight Corporation - Bethlehem PA

A61B 5/1455

600323

In accordance with the invention, the oxygenation of blood-profused tissue is measured by shining light into the profused tissue and analyzing the light reflected within the tissue. The light is reflected by cell walls in the tissue and is partially absorbed by hemoglobin in the blood. Since the extent of absorption is sensitive to the extent of hemoglobin oxygenation, measurement and processing of the reflected light provides a measure of the oxygenation of the blood. In one embodiment, the method is applied to measure the oxygenation of blood within the tympanic membrane (ear drum).

7510849, Mar 31, 2009

Jan 21, 2005

11/040388

Matthew J. Schurman - Somerset NJ, US
Walter Jeffrey Shakespeare - Macungie PA, US

GlucoLight Corporation - Bethlehem PA

C12Q 1/54

435 14, 424 91

This invention relates to a method of diagnosing or treating a biological subject, such as a person or animal, comprising the steps of subjecting at least a microsample of the subject's tissue to a physiological perturbation and measuring the response of the microsample to the perturbation using optical coherence tomography (OCT). In an exemplary embodiment, the concentration of glucose in the microsample is perturbed, as by providing the subject with a high glucose drink, and subsequently monitoring at a high sample rate in a microsample by OCT. Pathology, such as diabetes, can be diagnosed by deviation of the concentration vs. time response over several cells (micro-oscillation) from the micro-oscillation in the cells of a healthy subject. Other applications include diagnosing or treating de-hydration and diseases that cause changes in the osmolyte concentrations and thus the osmotic pressure in the cells in tissue.

7822452, Oct 26, 2010

Apr 13, 2006

11/403635

Matthew J. Schurman - Somerset NJ, US
Walter J. Shakespeare - Macungie PA, US
William Henry Bennett - Bethlehem PA, US

GLT Acquisition Corp. - Irvine CA

A61B 5/1455

600316

The present invention relates to a method for estimating blood glucose levels using a noninvasive optical coherence tomography- (OCT-) based blood glucose monitor. An algorithm correlates OCT-based estimated blood glucose data with actual blood glucose data determined by invasive methods. OCT-based data is fit to the obtained blood glucose measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood glucose levels, it may refine the number of sets by applying one or more mathematical filters. The OCT-based blood glucose monitor is calibrated using an Intensity Difference plot or the Pearson Product Moment Correlation method.

8306596, Nov 6, 2012

Sep 22, 2010

12/888318

Matthew J. Schurman - Somerset NJ, US
Walter J. Shakespeare - Macungie PA, US
William Henry Bennett - Bethlehem PA, US

GLT Acquisition Corp. - Irvine CA

A61B 5/1455

600322, 600316

The present invention relates to a method and system for estimating blood analyte levels using a noninvasive optical coherence tomography (OCT) based physiological monitor. An algorithm correlates OCT-based estimated blood analyte data with actual blood analyte data determined by other methods, such as invasively. OCT-based data is fit to the obtained blood analyte measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood analyte levels, it may refine the number of sets by applying one or more mathematical filters. The OCT-based physiological monitor can be calibrated using an Intensity Difference plot or the Pearson Product Moment Correlation method.

8548549, Oct 1, 2013

Sep 9, 2011

13/229410

Matthew J. Schurman - Somerset NJ, US
Walter J. Shakespeare - Macungie PA, US
William Henry Bennett - Bethlehem PA, US

GLT Acquisition Corp. - Irvine CA

A61B 5/1455

600328, 600322, 600326

A method for noninvasively measuring analyte levels includes using a non-imaging OCT-based system to scan a two-dimensional area of biological tissue and gather data continuously during the scanning. Structures within the tissue where measured-analyte-induced changes to the OCT data dominate over changes induced by other analytes are identified by focusing on highly localized regions of the data curve produced from the OCT scan which correspond to discontinuities in the OCT data curve. The data from these localized regions then can be related to measured analyte levels.

8571617, Oct 29, 2013

Mar 4, 2009

12/397593

Samuel Reichgott - Coopersburg PA, US
Walter J. Shakespeare - Macungie PA, US
George Kechter - Peoria IL, US
Phillip William Wallace - Bernardsville NJ, US
Matthew J. Schurman - Somerset NJ, US

GLT Acquisition Corp. - Irvine CA

A61B 5/00
A61B 5/02

600310, 600322, 600504

Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e. g. , blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e. g. , glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.

20060063988, Mar 23, 2006

Aug 11, 2004

10/916236

Matthew Schurman - Somerset NJ, US
Walter Shakespeare - Macungie PA, US

A61B 5/00

600316000

In accordance with the invention, a low coherence interferometer is used to non-invasively monitor the concentration of glucose in blood by shining a light over a surface area of human or animal tissue, continuously scanning the light over a two dimensional area of the surface, collecting the reflected light from within the tissue and constructively interfering this reflected light with light reflected along a reference path to scan the tissue in depth. Since the reflection spectrum is sensitive to glucose concentration at particular wavelengths, measurement and analysis of the reflected light provides a measure of the level of glucose in the blood. The measurement of glucose is taken from multiple depths within blood-profused tissue, and sensitivity is preferably enhanced by the use of multiple wavelengths. Noise or speckle associated with this technique is minimized by continuously scanning the illuminated tissue in area and depth.

20100113900, May 6, 2010

Mar 4, 2009

12/397577

Walter J. Shakespeare - Macungie PA, US
William Henry Bennett - Bethlehem PA, US
Jason T. Iceman - Allentown PA, US
Howard P. Apple - Winter Park FL, US
Phillip William Wallace - Bernardsville NJ, US
Matthew J. Schurman - Somerset NJ, US

GlucoLight Corporation - Bethlehem PA

A61B 5/1455

600316

Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.